Bone marrow derived neural stem cell therapy for glioma
骨髓源性神经干细胞治疗神经胶质瘤
基本信息
- 批准号:7215672
- 负责人:
- 金额:$ 30.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-07-01 至 2009-03-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAdultApoptosisAreaAstrocytesAutologousBehaviorBiologyBone MarrowBrainBrain NeoplasmsCXCRCXCR4 geneCell ProliferationCell membraneCell physiologyCellsClinicalConditioned Culture MediaCytotoxic T-LymphocytesDiseaseDoctor of MedicineDrug Delivery SystemsEngraftmentGene TransferGene Transfer TechniquesGenesGlial Fibrillary Acidic ProteinGlioblastomaGliomaGoalsHippocampus (Brain)ImplantIn VitroInvestigationLeadLigandsMalignant GliomaMethodsMigration AssayModelingMusNatureNerve DegenerationNeuronsNumbersOligodendrogliaPhenotypeProcessProgress Review GroupProliferatingProtein OverexpressionPurposeRadiosurgeryRecurrenceRefractoryResearch PersonnelRodentSourceStem cellsStromal CellsTestingTherapeutic AgentsTissuesTransfer FactorTranslatingTransplantationTropismbasecell motilitychemotherapycytotoxicfetalimplantationimprovedin vivomigrationneoplasticneoplastic cellnerve stem cellnervous system disordernovelnovel therapeuticsprogenitorprogramsreceptorrelating to nervous systemresponsestem cell therapytherapeutic genetherapeutic targettraffickingtumor
项目摘要
DESCRIPTION (provided by applicant): The capacity of neural stem cells (NSC) to migrate towards areas of tissue damage within the brain underscores the potential use of these cells as agents for cell replacement and/or drug delivery in the brain. Malignant gliomas consist of infiltrating tumor cells, which are largely refractory to currently employed therapies, resulting in inevitable tumor recurrence. We have demonstrated the efficacy of using primary fetal murine NSC as delivery vehicles for cytotoxic or immunostimulatory agents to treat infiltrating glioma and have demonstrated a mechanism of glioma tropism. We also described a rapid culture process whereby multipotent neural precursors, phenotypically and morphologically distinct from bone marrow stromal cells can be generated from unfractionated adult bone marrow. These bone marrow derived neural progenitors (BM-NSC) are morphologically and phenotypically indistinguishable from fetal NSC and could differentiate into neurons, astrocytes, and oligodendroglia. BM-NSC demonstrated tumor tropic behavior in vivo and when inoculated into the hippocampus, engrafted and assumed neuronal phenotype. These findings indicate that adult bone marrow may serve as a viable source of neural progenitor cells to treat glioma and neurodegeneration. We now aim to test the hypotheses that: 1) Bone marrow derived NSC (BM-NSC) migration toward glioma is dependent on CXCR4 expression on the plasma membrane of BM-NSC. 2) BM-NSC differentiation into A2B5+, GFAP+ astrocytic precursors will promote migration toward glioma, while terminal differentiation into neurons will promote engraftment after intracranial transplantation. 3) Overexpression of Shh or Gli-1 will promote BM-NSC proliferation, while Nurr1 will promote neuronal fate and Delta-like ligand 1 will promote astrocytic fate. 4) Promoting BM-NSC proliferation and astrocytic fate will (i) lead to increased migration to glioma and (ii) increase tumor control and prolong survival in an experimental rodent glioma model.
描述(由申请人提供):神经干细胞(NSC)向脑内组织损伤区域迁移的能力强调了这些细胞作为脑中细胞替代和/或药物递送试剂的潜在用途。恶性神经胶质瘤由浸润性肿瘤细胞组成,其在很大程度上对目前采用的疗法是难治的,导致不可避免的肿瘤复发。我们已经证明了使用原代胎鼠NSC作为细胞毒性或免疫刺激剂的递送载体来治疗浸润性胶质瘤的功效,并且已经证明了胶质瘤嗜性的机制。我们还描述了一种快速培养方法,即多能神经前体细胞,表型和形态学上不同于骨髓基质细胞,可以从普通成人骨髓产生。这些骨髓源性神经祖细胞(BM-NSC)在形态学和表型上与胎儿NSC无法区分,并且可以分化为神经元、星形胶质细胞和少突胶质细胞。BM-NSC在体内表现出肿瘤嗜性行为,并且当接种到海马中时,移植并呈现神经元表型。这些发现表明,成人骨髓可能作为一个可行的来源,神经祖细胞治疗胶质瘤和神经变性。我们现在的目的是验证以下假设:1)骨髓源性NSC(BM-NSC)向胶质瘤的迁移依赖于BM-NSC质膜上CXCR 4的表达。2)BM-NSC分化为A2 B5+、GFAP+星形胶质细胞前体将促进向胶质瘤的迁移,而终末分化为神经元将促进颅内移植后的植入。3)Shh或Gli-1的过表达将促进BM-NSC增殖,而Nurr 1将促进神经元命运,Delta样配体1将促进星形胶质细胞命运。4)促进BM-NSC增殖和星形胶质细胞命运将(i)导致向胶质瘤的迁移增加和(ii)增加肿瘤控制并延长实验啮齿动物胶质瘤模型中的存活。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John S Yu其他文献
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
- DOI:
10.1186/1476-4598-5-67 - 发表时间:
2006-12-01 - 期刊:
- 影响因子:33.900
- 作者:
Gentao Liu;Xiangpeng Yuan;Zhaohui Zeng;Patrizia Tunici;Hiushan Ng;Iman R Abdulkadir;Lizhi Lu;Dwain Irvin;Keith L Black;John S Yu - 通讯作者:
John S Yu
John S Yu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John S Yu', 18)}}的其他基金
Magnetofluorescent nanoplatform for glioblastoma therapy
用于胶质母细胞瘤治疗的磁荧光纳米平台
- 批准号:
10472011 - 财政年份:2020
- 资助金额:
$ 30.79万 - 项目类别:
Magnetofluorescent nanoplatform for glioblastoma therapy
用于胶质母细胞瘤治疗的磁荧光纳米平台
- 批准号:
10060454 - 财政年份:2020
- 资助金额:
$ 30.79万 - 项目类别:
Magnetofluorescent nanoplatform for glioblastoma therapy
用于胶质母细胞瘤治疗的磁荧光纳米平台
- 批准号:
10686322 - 财政年份:2020
- 资助金额:
$ 30.79万 - 项目类别:
Magnetofluorescent nanoplatform for glioblastoma therapy
用于胶质母细胞瘤治疗的磁荧光纳米平台
- 批准号:
10261527 - 财政年份:2020
- 资助金额:
$ 30.79万 - 项目类别:
Targeting cancer stem cells for brain tumor therapy
靶向癌症干细胞进行脑肿瘤治疗
- 批准号:
7585750 - 财政年份:2008
- 资助金额:
$ 30.79万 - 项目类别:
Targeting cancer stem cells for brain tumor therapy
靶向癌症干细胞进行脑肿瘤治疗
- 批准号:
7362200 - 财政年份:2008
- 资助金额:
$ 30.79万 - 项目类别:
Human Bone Marrow Derived Neural Stem Cell Therapy
人骨髓源性神经干细胞疗法
- 批准号:
6967358 - 财政年份:2005
- 资助金额:
$ 30.79万 - 项目类别:
Human Bone Marrow Derived Neural Stem Cell Therapy
人骨髓源性神经干细胞疗法
- 批准号:
7140455 - 财政年份:2005
- 资助金额:
$ 30.79万 - 项目类别:
Bone marrow derived neural stem cell therapy for glioma
骨髓源性神经干细胞治疗神经胶质瘤
- 批准号:
6807513 - 财政年份:2004
- 资助金额:
$ 30.79万 - 项目类别:
Bone marrow derived neural stem cell therapy for glioma
骨髓源性神经干细胞治疗神经胶质瘤
- 批准号:
8184969 - 财政年份:2004
- 资助金额:
$ 30.79万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 30.79万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 30.79万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 30.79万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 30.79万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 30.79万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 30.79万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 30.79万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 30.79万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 30.79万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 30.79万 - 项目类别:
Research Grant